Abstract library

314 results for "Hess".
#1078 Somatostatin Responsive ACTH and Precursor Excess in a Midgut Mesentery NET
Introduction: ACTH production from a midgut mesentery NET is extremely rare (1). A 62y old woman presented with hypokalaemia (2mmol/L) and hyperpigmentation, 11y after surgery of a pT3N1Mx non-functional G1 NET with SRS positive, non-resectable but stable, residual mass encasing mesenteric vessels. Serum cortisol (3261 nmol/L), ACTH (796 ng/L), CgA (530 pmol/L) and urine total cortisol metabolites (33920 µg/24h) including 14 sub-products indicated change of biological behaviour into a functioning NET. Pituitary or pulmonary sources were excluded
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr., Ass Prof. Martin O. Weickert
#163 Clinical value of MRI DWI and (Gd-EOB)-DTPA to assess liver involvement in patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Introduction: Standard MRI, including breath-hold techniques with SE T1 and T2 weighted images, biochemical shift, and 3D GRE and also T1 images after gadolinium enhancement Gd-DTPA, are useful in detecting liver lesions in patients with advanced GEP-NET. Recently, new algorithms of MRI, including diffusion-weighted imaging MRI (DWI) and i.v. (Gd-EOB)-DTPA (Primovist) contrast enhancement, seems to be promising in the detection of liver deposits.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Jaroslaw B Cwikla
#209 A Randomized, Cross-Over Study in Patients with Neuroendocrine Tumors (NETs) to Assess Patient Preference of Lanreotide Autogel Given by Either Self/Partner or Healthcare Professional
Introduction: Ready-to-use Lanreotide Autogel provides the option of self/partner administration for patients with NET. This is anticipated to reduce treatment cost and negative impact on daily life.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MSc Anders Öhberg
#903 Health-Related Quality-of-Life (HRQoL) in Patients (pts) with Advanced Neuroendocrine Tumors (NET) Treated with Everolimus (EVE): Results from an Open-label, Phase IIIb, Multicenter, Expanded Access Program (EAP)
Introduction: NET is associated with a considerable HRQoL burden.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Marianne Pavel
Authors: Pavel M, Unger N, Borbath I, Ricci S, ...
Keywords: everolimus, QoL, NET
#1606 Tumor Growth Rate to Assess Tumor Activity in Patients with Lung Neuroendocrine Tumors on Lanreotide Autogel: A Case-Series Analysis
Introduction: The slow-growing character of neuroendocrine tumors (NET) makes it difficult to assess treatment impact on tumor growth.
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Frank van Fraeyenhove
#1714 CALM-NET, A Multicentre, Exploratory Study to Assess the Clinical Value of Circulating Tumour Cells (CTCs) Enumeration in Patients (Pts) with Functioning Midgut NETs Receiving Lanreotide Autogel (LAN)
Introduction: The presence of CTCs confers adverse prognosis in metastatic NET pts with heterogenous treatment history. Post treatment CTC count correlates with disease progression and overall survival.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Kate Higgs
#1851 Ecological Study to Assess the Management of Gastroenteropancreatic Neuroendocrine Tumors in Spain
Introduction: Neuroendocrine tumors (NET) have widely varying characteristics, localizations, and treatments. Consequently, a multidisciplinary approach to diagnosis and treatment is necessary. Given the heterogeneous management of this disease, we conducted an ecological survey to assess usual clinical practice in Spain.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Raquel Guardeño
#1349 Access to Care and Outcomes for Neuroendocrine Tumors: Does Socio-Economic Status Matter? A Population-Based Analysis.
Introduction: Neuroendocrine Tumors (NET) lack standardized care. Differences in socioeconomic status (SES) worsen the impact of non-standardized care.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Hallet Julie
#1104 Interlaboratory Variability of MIB1 Staining in Well Differentiated Pancreatic Neuroendocrine Tumors
Introduction: In neuroendocrine tumors (NET) grading and staging are the only routinely performed procedures to judge prognosis. Proliferation index using MIB1 staining has been introduced to assess grading. There are discussions on cut-off definitions, automated counting and inter-observer variability.
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: Dr. Blank Annika
Authors: Blank A, Wehweck L, Marinoni I, Boos L, ...
Keywords: MIB1, Ki67, grading, NET
#1319 Neuroendocrine Cancer Patient Experience Survey
Introduction: Annually a national patient cancer survey (NCPES) is performed to assess perceived patient care. It was noted that in the previous cancer experience surveys patients with NET had not been invited to participate. The NET Patient Foundation (NETPF) commissioned Quality Health to undertake this survey in patients with a known diagnosis of neuroendocrine cancer. The patients were identified via NET centres of excellence around England.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Catherine Bouvier